First-Ever Survival Bump in Relapsed Mesothelioma

(MedPage Today) -- Patients with progressive mesothelioma obtained a first-ever survival improvement with nivolumab (Opdivo) as second-line therapy, a randomized trial showed.
Median overall survival (OS) increased by almost 40%, and the progress...